Table 1.
Baseline characteristics of the study population
| Baseline characteristics of future MI cases (N = 744) | Baseline characteristics of the total cohort (N = 9499) | |
|---|---|---|
| Age in years (mean (SD)) | 69.7 (8.1) | 69.4 (8.7) |
| Female (N (%)) | 333 (44.8) | 5787 (60.9) |
| Body mass index in kg/m2 (mean (SD)) | 26.8 (3.4) | 26.7 (3.8) |
| Current smoking (N (%)) | 194 (26.1) | 1908 (20.1) |
| Education (N (%)) | ||
| Basic | 145 (19.5) | 1,870 (19.7) |
| Low | 295 (39.5) | 4,156 (43,8) |
| Medium | 215 (28.9) | 2,465 (26.0) |
| High | 90 (12.1) | 1,008 (10.6) |
| Systolic blood pressure in mmHg (mean (SD)) | 146 (21) | 132 (21) |
| Diastolic blood pressure in mmHg (mean (SD)) | 77 (11) | 77 (11) |
| Total cholesterol in mmol/L (mean (SD)) | 6.7 (1.2) | 6.4 (1.2) |
| HDL cholesterol in mmol/L (mean (SD)) | 1.2 (0.3) | 1.4 (0.4) |
| History of venous thromboembolism (N (%)) | 2 (0.3) | 13 (0.1) |
| History of heart failure (N (%)) | 22 (3.0) | 239 (2.5) |
| Depression (N (%)) | 4 (0.5) | 86 (1.0) |
| Anxiety (N (%)) | 2 (0.3) | 53 (0.6) |
| Glucose-lowering agents (N (%)) | 73 (9.8) | 476 (5.0) |
| Antithrombotic agents (N (%)) | 86 (11.6) | 1035 (10.9) |
| Blood-pressure-lowering agents (N (%)) | 172 (23.1) | 2098 (22.1) |
| Beta-blockers (N (%)) | 142 (19.1) | 1246 (13.1) |
| Lipid-lowering agents (N (%)) | 40 (5.4) | 524 (5.5) |
| Antipsychotics (N (%)) | 5 (0.7) | 87 (0.9) |
| Anxiolytics (N (%)) | 31 (4.2) | 453 (4.8) |
| Hypnotics (N (%)) | 47 (6.3) | 540 (5.7) |
Abbreviations: N number of participants, SD standard deviation, HDL high-density lipoprotein